RGBP Regen BioPharma Inc
Pharmaceutical Preparations · OTC · SEC CIK 1589150 · Fiscal year ends 09/30
Financial factors as of 2026-06-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY0.0%
TTM net income YoY-54.5%
TTM EPS YoY77.8%
Revenue 3-yr CAGR15.4%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-339.8%
Net margin-501.4%
FCF margin—
EBITDA margin—
Returns
ROE—
ROA-489.7%
ROIC (approx.)—
Asset turnover0.98x
Leverage & solvency
Liabilities / assets2,144.0%
Debt / equity—
Current ratio0.05x
Interest coverage-4.72x
Cash quality & payout
Operating cash flow / net income0.38x
Accruals ratio-305.9%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-06-30 | 2026Q22026-03-31 | 2026Q12025-12-31 | 2025Q4*2025-09-30 | 2025Q32025-06-30 | 2025Q22025-03-31 | 2025Q12024-12-31 | 2024Q4*2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $59,065 | $59,065 | $59,065 | $59,366 | $59,065 | $59,065 | $59,065 | $59,366 |
| R&D expense | $0 | $2,216 | $210,000 | $11,725 | $0 | $0 | $0 | $33,524 |
| SG&A expense | $13,842 | $32,104 | $231,925 | $17,749 | $30,697 | $13,348 | $13,317 | $20,622 |
| Operating income | $24,528 | -$153,709 | -$551,624 | -$123,055 | -$40,756 | -$113,349 | -$61,378 | -$85,402 |
| Interest expense | $30,360 | $27,388 | $26,553 | $85,967 | $24,638 | $22,329 | $25,352 | $20,063 |
| Pretax income | -$637,785 | $991,927 | -$967,853 | -$572,469 | -$167,292 | -$19,354 | -$515,384 | -$270,748 |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$637,785 | $991,927 | -$967,853 | -$572,469 | -$167,292 | -$19,354 | -$515,384 | -$65,902 |
| EPS (basic) | 0.00 | 0.00 | -0.01 | — | -0.01 | 0.00 | -0.13 | — |
| EPS (diluted) | 0.00 | 0.00 | -0.01 | — | -0.01 | 0.00 | -0.13 | — |
| Weighted avg. shares (diluted) | 615.56M | 184.94M | 99.61M | — | 23.75M | 21.55M | 4.11M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $239 | $271 | $4,578 | $69,555 | $1,761 | $1,761 | $135 | $716 |
| Receivables | $287,147 | $259,723 | $232,298 | $204,873 | $177,147 | $149,723 | $122,298 | $94,873 |
| Current assets | $287,587 | $260,194 | $237,076 | $274,628 | $179,108 | $151,749 | $173,683 | $143,351 |
| Total assets | $287,587 | $260,194 | $237,076 | $274,628 | $196,841 | $169,482 | $191,416 | $161,084 |
| Current liabilities | $6.17M | $5.62M | $6.81M | $6.56M | $6.01M | $5.87M | $5.87M | $5.38M |
| Total liabilities | $6.17M | $5.62M | $6.81M | $6.56M | $6.01M | $5.87M | $5.87M | $5.38M |
| Shareholders' equity | -$5.88M | -$5.36M | -$6.57M | -$6.28M | -$5.82M | -$5.70M | -$5.68M | -$5.22M |
| Shares outstanding | 1.13B | 351.44M | 108.05M | 39.37M | 31.55M | 21.55M | 21.55M | 5.26M |
| Cash flow statement | ||||||||
| Operating cash flow | -$24,069 | -$63,234 | -$197,941 | -$160,005 | -$55,977 | -$101,230 | -$66,379 | -$207,290 |
| Financing cash flow | $24,037 | $58,926 | $132,964 | $227,799 | $55,976 | $102,856 | $65,799 | $146,157 |
| Stock-based compensation | — | — | — | — | — | — | — | $10,724 |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.